Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health.


Journal

Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730

Informations de publication

Date de publication:
01 12 2022
Historique:
received: 08 08 2022
revised: 03 09 2022
accepted: 21 09 2022
pubmed: 30 9 2022
medline: 19 10 2022
entrez: 29 9 2022
Statut: ppublish

Résumé

Obesity, type 2 diabetes (T2DM), hypertension (HTN), and Cardiovascular Disease (CVD) often cluster together as "Cardiometabolic Disease" (CMD). Just under 50% of patients with CMD increased the risk of morbidity and mortality right from the beginning of the COVID-19 pandemic as it has been reported in most countries affected by the SARS-CoV2 virus. One of the pathophysiological hallmarks of COVID-19 is the overactivation of the immune system with a prominent IL-6 response, resulting in severe and systemic damage involving also cytokines such as IL2, IL4, IL8, IL10, and interferon-gamma were considered strong predictors of COVID-19 severity. Thus, in this mini-review, we try to describe the inflammatory state, the alteration of the adipokine profile, and cytokine production in the obese state of infected and not infected patients by SARS-CoV2 with the final aim to find possible influences of COVID-19 on CMD and CVD. The immunological-based discussion of the molecular processes could inspire the study of promising targets for managing CMD patients and its complications during COVID-19.

Identifiants

pubmed: 36174875
pii: S0925-4439(22)00230-7
doi: 10.1016/j.bbadis.2022.166559
pmc: PMC9510069
pii:
doi:

Substances chimiques

Adipokines 0
Cytokines 0
Interleukin-2 0
Interleukin-6 0
Interleukin-8 0
RNA, Viral 0
Interleukin-10 130068-27-8
Interleukin-4 207137-56-2
Interferon-gamma 82115-62-6

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

166559

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: None reports was provided by none. None reports a relationship with none that includes: None has patent pending to none. None.

Références

J Clin Med. 2021 May 01;10(9):
pubmed: 34062770
Front Immunol. 2022 May 18;13:894470
pubmed: 35663992
Front Med (Lausanne). 2021 Mar 18;8:620990
pubmed: 33816521
Glob Heart. 2022 Jan 12;17(1):2
pubmed: 35174043
Front Pharmacol. 2021 Apr 29;12:654425
pubmed: 33995071
Theranostics. 2021 Jul 13;11(17):8234-8253
pubmed: 34373739
Arq Bras Cardiol. 2020 May 11;114(5):805-816
pubmed: 32401847
Obesity (Silver Spring). 2020 Jul;28(7):1191-1194
pubmed: 32314868
Int J Obes (Lond). 2021 Sep;45(9):2028-2037
pubmed: 34112941
Cells. 2022 Feb 04;11(3):
pubmed: 35159352
J Diabetes Complications. 2021 Mar;35(3):107817
pubmed: 33358523
J Pers Med. 2022 Mar 03;12(3):
pubmed: 35330391
Diabetes Res Clin Pract. 2020 Nov;169:108521
pubmed: 33096190
Sci Rep. 2021 Nov 2;11(1):21514
pubmed: 34728695
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Epidemiol Infect. 2021 Jan 05;149:e144
pubmed: 33397542
Lancet Glob Health. 2020 Aug;8(8):e1003-e1017
pubmed: 32553130
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Eur J Med Res. 2020 Dec 2;25(1):64
pubmed: 33267871
Heliyon. 2020 Aug;6(8):e04696
pubmed: 32844126
Cell Mol Immunol. 2021 Oct;18(10):2457-2459
pubmed: 34465884
Mediators Inflamm. 2019 Apr 28;2019:7538071
pubmed: 31182932
Prim Care Diabetes. 2021 Feb;15(1):194
pubmed: 32900656
Arch Med Sci. 2020 Jun 27;17(2):275-284
pubmed: 33747262
Arch Med Sci. 2021 Mar 18;17(3):818-822
pubmed: 34025853
J Biol Chem. 2022 Mar;298(3):101695
pubmed: 35143839
Eur Respir J. 2020 Jun 4;55(6):
pubmed: 32350105
Int J Obes (Lond). 2022 Jul;46(7):1254-1261
pubmed: 35393519
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Int J Obes (Lond). 2020 Sep;44(9):1810-1817
pubmed: 32647360
N Engl J Med. 2020 Feb 6;382(6):545-553
pubmed: 32023374
Nat Med. 2019 Nov;25(11):1644-1646
pubmed: 31700172
Obes Facts. 2020;13(4):430-438
pubmed: 32659766
Diabetes Ther. 2022 Oct;13(10):1723-1736
pubmed: 36030317
J Physiol Biochem. 2022 Aug;78(3):581-591
pubmed: 35316507
Front Immunol. 2021 Jun 18;12:649359
pubmed: 34220807
Int J Obes (Lond). 2020 Aug;44(8):1800-1802
pubmed: 32514077
Life Sci. 2020 Oct 1;258:118167
pubmed: 32735885
Eur Heart J. 2022 Mar 14;43(11):1033-1058
pubmed: 34791157
PLoS One. 2020 Aug 25;15(8):e0237974
pubmed: 32841271
JAMA Cardiol. 2020 Nov 1;5(11):1281-1285
pubmed: 32730555
ERJ Open Res. 2021 Aug 02;7(3):
pubmed: 34350288
Cytokine Growth Factor Rev. 2020 Jun;53:38-42
pubmed: 32360420
Int J Mol Sci. 2021 Nov 03;22(21):
pubmed: 34769350
Neurosci Res. 2020 Sep;158:1-5
pubmed: 32628969
Signal Transduct Target Ther. 2020 May 29;5(1):84
pubmed: 32467561
Int J Clin Pract. 2021 Feb;75(2):e13666
pubmed: 32770758
Lancet Respir Med. 2020 Mar;8(3):267-276
pubmed: 32043986
Diabetes Metab. 2021 Nov;47(6):101268
pubmed: 34333093
J Cardiovasc Pharmacol. 2021 Jul 1;78(1):e1-e2
pubmed: 34173808
Brain Sci. 2021 Apr 02;11(4):
pubmed: 33918426
Int J Med Sci. 2022 Jan 24;19(2):402-415
pubmed: 35165525
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Med Virol. 2020 Oct;92(10):2105-2113
pubmed: 32383269
Metab Syndr Relat Disord. 2020 May;18(4):173-175
pubmed: 32271125
J Diabetes Complications. 2021 Feb;35(2):107809
pubmed: 33288414
Diabetes Obes Metab. 2021 Mar;23(3):870-874
pubmed: 33245182
J Diabetes Complications. 2021 Dec;35(12):108054
pubmed: 34600823
Diabetes Res Clin Pract. 2020 May;163:108151
pubmed: 32305399
Int J Mol Sci. 2021 May 16;22(10):
pubmed: 34065735
J Med Virol. 2021 Dec;93(12):6634-6640
pubmed: 34314067
Cell Death Discov. 2019 Jun 5;5:101
pubmed: 31231549
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580
Front Cardiovasc Med. 2021 Dec 15;8:787761
pubmed: 34977193
Rev Med Virol. 2020 Nov;30(6):1-9
pubmed: 32845568
Sci Rep. 2021 Feb 3;11(1):2941
pubmed: 33536486
Circulation. 2020 Sep 22;142(12):1176-1189
pubmed: 32755393
Int J Obes (Lond). 2021 Sep;45(9):2126-2131
pubmed: 34059786
Cell. 2021 Jan 7;184(1):149-168.e17
pubmed: 33278357
Obesity (Silver Spring). 2021 Apr;29(4):645-653
pubmed: 33270351
Trends Immunol. 2019 Sep;40(9):857-872
pubmed: 31399336
Scand J Immunol. 2021 Feb;93(2):e12960
pubmed: 32797724
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093

Auteurs

Elena Lo Presti (E)

Institute for Biomedical Research and Innovation, National Research Council, Palermo, Italy. Electronic address: elena.lopresti@cnr.it.

Domenico Nuzzo (D)

Institute for Biomedical Research and Innovation, National Research Council, Palermo, Italy.

Wael Al Mahmeed (W)

Heart and Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates.

Khalid Al-Rasadi (K)

Medical Research Center, Sultan Qaboos University, Muscat, Oman.

Kamila Al-Alawi (K)

Department of Training and Studies, Royal Hospital, Ministry of Health, Muscat, Oman.

Maciej Banach (M)

Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.

Yajnavalka Banerjee (Y)

Department of Biochemistry, Mohamed Bin Rashid University, Dubai, United Arab Emirates.

Antonio Ceriello (A)

IRCCS MultiMedica, Milan, Italy.

Mustafa Cesur (M)

Clinic of Endocrinology, Ankara Güven Hospital, Ankara, Turkey.

Francesco Cosentino (F)

Unit of Cardiology, Karolinska Institute and Karolinska University Hospital, University of Stockholm, Sweden.

Alberto Firenze (A)

Unit of Research and International Cooperation, University Hospital of Palermo, Italy.

Massimo Galia (M)

Department of Biomedicine, Neurosciences and Advanced Diagnostics (Bind), University of Palermo, Italy.

Su-Yen Goh (SY)

Department of Endocrinology, Singapore General Hospital, Singapore.

Andrej Janez (A)

Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Slovenia.

Sanjay Kalra (S)

Department of Endocrinology, Bharti Hospital & BRIDE, Karnal, India.

Nitin Kapoor (N)

Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.

Peter Kempler (P)

Department of Medicine and Oncology, Semmelweis University, Budapest, Hungary.

Nader Lessan (N)

The Research Institute, Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates.

Paulo Lotufo (P)

Center for Clinical and Epidemiological Research, University Hospital, University of São Paulo, Brazil.

Nikolaos Papanas (N)

Diabetes Center, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece.

Ali A Rizvi (AA)

Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.

Amirhossein Sahebkar (A)

Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Raul D Santos (RD)

Heart Institute (InCor) University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil; Hospital Israelita Albert Einstein, Sao Paulo, Brazil.

Anca P Stoian (AP)

Faculty of Medicine, Diabetes, Nutrition and Metabolic Diseases, Carol Davila University, Bucharest, Romania.

Peter P Toth (PP)

Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Vijay Viswanathan (V)

Diabetes Research Centre, Chennai, India.

Manfredi Rizzo (M)

Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Italy. Electronic address: manfredi.rizzo@unipa.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH